PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23604281-0 2013 Genetic polymorphisms of ERCC1-118, XRCC1-399 and GSTP1-105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin-based adjuvant chemotherapy. Oxaliplatin 138-149 glutathione S-transferase pi 1 Homo sapiens 50-55 24847383-0 2014 ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy. Oxaliplatin 108-119 glutathione S-transferase pi 1 Homo sapiens 17-22 24765164-0 2014 Long-term administration and efficacy of oxaliplatin with no neurotoxicity in a patient with rectal cancer: Association between neurotoxicity and the GSTP1 polymorphism. Oxaliplatin 41-52 glutathione S-transferase pi 1 Homo sapiens 150-155 24765164-12 2014 Therefore, correlation between the GSTP1 polymorphism and oxaliplatin-induced neurotoxicity remains controversial. Oxaliplatin 58-69 glutathione S-transferase pi 1 Homo sapiens 35-40 24137384-11 2013 GSTP1-105 and GSTM1 genotypes may be useful markers of severe peripheral neuropathy in MCRC patients treated with 5-FU/oxaliplatin as first-line chemotherapy. Oxaliplatin 119-130 glutathione S-transferase pi 1 Homo sapiens 0-5 23695028-0 2013 Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis. Oxaliplatin 53-64 glutathione S-transferase pi 1 Homo sapiens 20-25 23695028-1 2013 BACKGROUND AND AIMS: The association between glutathione-S-transferase P1 (GSTP1) Ile105Val polymorphism and oxaliplatin-induced neuropathy has been investigated in a number of published studies. Oxaliplatin 109-120 glutathione S-transferase pi 1 Homo sapiens 45-73 23695028-1 2013 BACKGROUND AND AIMS: The association between glutathione-S-transferase P1 (GSTP1) Ile105Val polymorphism and oxaliplatin-induced neuropathy has been investigated in a number of published studies. Oxaliplatin 109-120 glutathione S-transferase pi 1 Homo sapiens 75-80 23695028-3 2013 To assess the relationship between GSTP1 gene Ile105Val polymorphism and its susceptibility to oxaliplatin-induced neuropathy, a meta-analysis of previous studies was conducted. Oxaliplatin 95-106 glutathione S-transferase pi 1 Homo sapiens 35-40 23299794-0 2013 XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis. Oxaliplatin 47-58 glutathione S-transferase pi 1 Homo sapiens 10-15 23299794-2 2013 The aim was to explore the influences of X-ray repair cross-complementing 1(XRCC1) and Glutathione S-transferase P1 (GSTP1) genetic variants on prognosis of oxaliplatin-based chemotherapy in colorectal cancer patients. Oxaliplatin 157-168 glutathione S-transferase pi 1 Homo sapiens 87-115 23299794-2 2013 The aim was to explore the influences of X-ray repair cross-complementing 1(XRCC1) and Glutathione S-transferase P1 (GSTP1) genetic variants on prognosis of oxaliplatin-based chemotherapy in colorectal cancer patients. Oxaliplatin 157-168 glutathione S-transferase pi 1 Homo sapiens 117-122 21940361-0 2012 Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer. Oxaliplatin 70-81 glutathione S-transferase pi 1 Homo sapiens 45-50 22994779-2 2012 We assessed whether single nucleotide polymorphisms (SNPs) in GSTP1, ERCC1 Asn118Asn and ERCC2 Lys751Gln might predict the overall survival in patients receiving oxaliplatin-based chemotherapy in a Chinese population. Oxaliplatin 162-173 glutathione S-transferase pi 1 Homo sapiens 62-67 22994779-8 2012 CONCLUSION: GSTP1, GSTP1, ERCC1 Asn118Asn and ERCC2 Lys751Gln genotyping might facilitate tailored oxaliplatin-based chemotherapy for colorectal cancer patients. Oxaliplatin 99-110 glutathione S-transferase pi 1 Homo sapiens 12-17 21940361-9 2012 CONCLUSIONS: Immunohistochemical studies for ERCC-1 and GST-p may be useful in prediction of the response to 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer patients. Oxaliplatin 124-135 glutathione S-transferase pi 1 Homo sapiens 56-61 21468552-7 2011 A similar reaction has also been observed in patients with the XRCC1 Arg399Gln polymorphism, while patients with the GSTP1 Ile105Val polymorphism have an improved response to oxaliplatin/5FU therapy. Oxaliplatin 175-186 glutathione S-transferase pi 1 Homo sapiens 117-122 21787681-8 2011 Whereas, bus drivers with GSTP1 Val and GSTM1 null genotypes showed decreasing in excretion of 1-OHP. Oxaliplatin 95-100 glutathione S-transferase pi 1 Homo sapiens 26-31 21787681-10 2011 This study indicated that 1-OHP concentrations were associated with exposure to air pollution, cigarette smoking and polymorphisms of CYP1A1, GSTM1 and GSTP1 genes. Oxaliplatin 26-31 glutathione S-transferase pi 1 Homo sapiens 152-157 20979931-0 2010 Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Oxaliplatin 21-32 glutathione S-transferase pi 1 Homo sapiens 98-103 21619788-1 2011 OBJECTIVE: To investigate the modification of GSTM1, GSTT1 and GSTP1 gene polymorphisms on urinary 1-hydroxypyrene (1-OHP) excretions in workers under different exposure levels. Oxaliplatin 116-121 glutathione S-transferase pi 1 Homo sapiens 63-68 21619788-5 2011 After controlling potential confounders, decreased excretion of urinary 1-OHP was associated with GSTP1 I105V AG + GG genotype in coke oven workers (single-gene model, P = 0.012; multi-gene model, P = 0.011) and with GSTT1 null type in the analysis including all subjects (P = 0.055 in both single-gene and multi-gene models). Oxaliplatin 72-77 glutathione S-transferase pi 1 Homo sapiens 98-103 21619788-6 2011 GSTT1 and GSTP1 were interacted on the urinary concentrations of 1-OHP. Oxaliplatin 65-70 glutathione S-transferase pi 1 Homo sapiens 10-15 21619788-7 2011 CONCLUSION: Urinary 1-OHP concentrations can be modified by GSTM1, GSTT1 and GSTP1 gene polymorphisms, indicating that these genes are involved in the metabolism of polycyclic aromatic hydrocarbons. Oxaliplatin 20-25 glutathione S-transferase pi 1 Homo sapiens 77-82 21029695-0 2010 [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy]. Oxaliplatin 128-139 glutathione S-transferase pi 1 Homo sapiens 60-65 21029695-10 2010 CONCLUSION: Genetic polymorphisms of ERCC1-118, XRCC1-399 and GSTP1-105 are associated with TTP and OS of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based combination chemotherapy as the first-line chemotherapy. Oxaliplatin 152-163 glutathione S-transferase pi 1 Homo sapiens 62-67 20047135-0 2009 Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin-based chemotherapy and clinical outcome in advanced colorectal cancer patients. Oxaliplatin 59-70 glutathione S-transferase pi 1 Homo sapiens 25-30 20514304-0 2010 Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. Oxaliplatin 65-76 glutathione S-transferase pi 1 Homo sapiens 24-29 20514304-1 2010 The aim of this study was to evaluate the predictive value of the polymorphism Glutathione S-transferase P1 (GSTP1) Ile(105)Val on oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. Oxaliplatin 131-142 glutathione S-transferase pi 1 Homo sapiens 79-107 20514304-1 2010 The aim of this study was to evaluate the predictive value of the polymorphism Glutathione S-transferase P1 (GSTP1) Ile(105)Val on oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. Oxaliplatin 131-142 glutathione S-transferase pi 1 Homo sapiens 109-114 20308030-2 2010 In this study, we investigated the associations between oxaliplatin-induced neuropathy and the following polymorphisms: glutathione S-transferase pi (GSTP1) Ile(105)Val, and glyoxylate aminotransferase (AGXT) Pro(11)Leu and AGXT Ile(340)Met. Oxaliplatin 56-67 glutathione S-transferase pi 1 Homo sapiens 150-155 19922504-10 2010 I105V polymorphism in GSTP1, by reducing its enzymatic activity and consequential detoxification to oxaliplatin, could be a key determinant for a better outcome, but more neurotoxicity, to FOLFOX-4 treatment. Oxaliplatin 100-111 glutathione S-transferase pi 1 Homo sapiens 22-27 20047135-8 2009 CONCLUSION: The GSTP1 105Val/105Val genotype is associated with a higher clinical response rate to oxaliplatin-based chemotherapy and with increased survival of patients with advanced colo-rectal cancer, receiving 5-FU/oxaliplatin chemotherapy. Oxaliplatin 99-110 glutathione S-transferase pi 1 Homo sapiens 16-21 20047135-8 2009 CONCLUSION: The GSTP1 105Val/105Val genotype is associated with a higher clinical response rate to oxaliplatin-based chemotherapy and with increased survival of patients with advanced colo-rectal cancer, receiving 5-FU/oxaliplatin chemotherapy. Oxaliplatin 219-230 glutathione S-transferase pi 1 Homo sapiens 16-21 19098406-0 2008 [Single nucleotide polymorphism analysis in the GSTP1 and ABCC2 genes about neuropathy by the Oxaliplatin]. Oxaliplatin 94-105 glutathione S-transferase pi 1 Homo sapiens 48-53 19084393-1 2009 PURPOSE: Oxaliplatin is detoxified by conjugation to glutathione via the enzyme Glutathione-S-transferase pi (GSTP1). Oxaliplatin 9-20 glutathione S-transferase pi 1 Homo sapiens 110-115 19084393-2 2009 The aim of this study is to investigate the association of GSTP1 Ile105Val genetic polymorphism with oxaliplatin efficacy and toxicity in advanced colorectal cancer (ACC) patients. Oxaliplatin 101-112 glutathione S-transferase pi 1 Homo sapiens 59-64 19247656-0 2009 Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Oxaliplatin 107-118 glutathione S-transferase pi 1 Homo sapiens 22-27 19247656-6 2009 CONCLUSION: Testing for p53 Arg72Pro, GSTP1 Ile105Val, and XRCC1 Arg399Gln polymorphisms may allow identification of gastric cancer patients who will benefit from oxaliplatin-based adjuvant chemotherapy. Oxaliplatin 163-174 glutathione S-transferase pi 1 Homo sapiens 38-43 19098406-11 2008 As for a successful rate of the treatment, the wild type and hetero type of GSTP1, a metabolism enzyme of Oxaliplatin, were 53.3% and 41.7%, respectively. Oxaliplatin 106-117 glutathione S-transferase pi 1 Homo sapiens 76-81 17498780-7 2007 These results showed that AhR, UGT1A1, GSTP1 and GSTT1 polymorphisms were associated with urinary 1-OHP concentrations in Chinese coke oven workers. Oxaliplatin 98-103 glutathione S-transferase pi 1 Homo sapiens 39-44 18633248-0 2008 [Impact of single nucleotide polymorphisms in glutathione S transferase gene GSTP1 in the treatment with oxaliplatin based chemotherapy]. Oxaliplatin 105-116 glutathione S-transferase pi 1 Homo sapiens 77-82 18633248-5 2008 Specific roles for the single nucleotide polymorphisms in GST-pi gene GSTP1 in the treatment with oxaliplatin based chemotherapy, have been demonstrated in recent years. Oxaliplatin 98-109 glutathione S-transferase pi 1 Homo sapiens 70-75 18085999-2 2007 The SNPs, Ile105Val for GSTP1 and Lys751Gln for ERCC2, may affect the efficiency of oxaliplatin in patients treated with an oxaliplatin-based regimen for metastatic colorectal carcinoma. Oxaliplatin 84-95 glutathione S-transferase pi 1 Homo sapiens 24-29 18085999-2 2007 The SNPs, Ile105Val for GSTP1 and Lys751Gln for ERCC2, may affect the efficiency of oxaliplatin in patients treated with an oxaliplatin-based regimen for metastatic colorectal carcinoma. Oxaliplatin 124-135 glutathione S-transferase pi 1 Homo sapiens 24-29 11600727-10 2001 There was less association between the concentrations of 1-OHP and the GSTM1, GSTP1, or GSTT1 polymorphism. Oxaliplatin 57-62 glutathione S-transferase pi 1 Homo sapiens 78-83 17322540-0 2007 Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Oxaliplatin 115-126 glutathione S-transferase pi 1 Homo sapiens 67-95 16707601-0 2006 Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Oxaliplatin 107-118 glutathione S-transferase pi 1 Homo sapiens 0-28 16707601-9 2006 The oxaliplatin-related cumulative neuropathy scored grade 3 was significantly more frequent in patients homozygous for the GSTP1 105Ile allele than in patients homozygous or heterozygous for the GSTP1 105Val allele (odds ratio, 5.75; 95% confidence interval, 1.08-30.74; P = 0.02). Oxaliplatin 4-15 glutathione S-transferase pi 1 Homo sapiens 124-129 16707601-9 2006 The oxaliplatin-related cumulative neuropathy scored grade 3 was significantly more frequent in patients homozygous for the GSTP1 105Ile allele than in patients homozygous or heterozygous for the GSTP1 105Val allele (odds ratio, 5.75; 95% confidence interval, 1.08-30.74; P = 0.02). Oxaliplatin 4-15 glutathione S-transferase pi 1 Homo sapiens 196-201 16707601-11 2006 CONCLUSIONS: The results of the current study suggest that the 105Val allele variant of the GSTP1 gene at exon 5 confers a significantly decreased risk of developing severe oxaliplatin-related cumulative neuropathy. Oxaliplatin 173-184 glutathione S-transferase pi 1 Homo sapiens 92-97 15890268-8 2005 Other appear determinant for drug response, such as the common SNPs found in glutathione S-transferase P1 or xereoderma pigmentosum group D enzyme for the activity of oxaliplatin. Oxaliplatin 167-178 glutathione S-transferase pi 1 Homo sapiens 77-105 15213713-2 2004 Functional polymorphisms in DNA-repair genes XPD, ERCC1, XRCC1, XPA, and metabolising genes glutathione S-transferase GSTP1, GSTT1, GSTM1, and thymidylate synthase (TS) were assessed retrospectively in 106 patients with refractory stage IV disease who received 5-FU/oxaliplatin combination chemotherapy, using a polymerase chain reaction-based RFLP technique. Oxaliplatin 266-277 glutathione S-transferase pi 1 Homo sapiens 118-123 17322540-1 2007 BACKGROUND: The aim of this study was to determine whether expressions of the excision repair cross-complementing (ERCC1), thymidylate synthase (TS), and glutathione S-transferase P1 (GSTP1) predict clinical outcome in patients with advanced gastric cancer treated with fluorouracil (5-fluorouracil)/oxaliplatin chemotherapy. Oxaliplatin 300-311 glutathione S-transferase pi 1 Homo sapiens 184-189 12072547-13 2002 CONCLUSIONS: The GSTP1 Ile(105)Val polymorphism is associated in a dose-dependent fashion with increased survival of patients with advanced colorectal cancer receiving 5-FU/oxaliplatin chemotherapy. Oxaliplatin 173-184 glutathione S-transferase pi 1 Homo sapiens 17-22 33035787-7 2020 In the oxaliplatin group, rs1045642 TT genotype was associated with the need to adjust treatment (OR = 0.32; p = 0.02), ERCC1 rs11615 GG genotype with asthenia (OR = 3.01; p = 0.01) and rs1615 GSTP1 GG genotype with respiratory toxicity (OR = 5.07; p = 0.009). Oxaliplatin 7-18 glutathione S-transferase pi 1 Homo sapiens 193-198 33280607-0 2020 Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms. Oxaliplatin 83-94 glutathione S-transferase pi 1 Homo sapiens 128-133 30372807-4 2018 There are different genes like GSTP1 and ABCB1 which are responsible for oxaliplatin resistance. Oxaliplatin 73-84 glutathione S-transferase pi 1 Homo sapiens 31-36 30854066-11 2019 The aforementioned indicated that GSTP1 genetic polymorphism is associated with peripheral neuropathy induced by oxaliplatin treatment for colorectal cancer, and therefore serves as a predictive marker. Oxaliplatin 113-124 glutathione S-transferase pi 1 Homo sapiens 34-39